JP2023528561A5 - - Google Patents
Info
- Publication number
- JP2023528561A5 JP2023528561A5 JP2022560025A JP2022560025A JP2023528561A5 JP 2023528561 A5 JP2023528561 A5 JP 2023528561A5 JP 2022560025 A JP2022560025 A JP 2022560025A JP 2022560025 A JP2022560025 A JP 2022560025A JP 2023528561 A5 JP2023528561 A5 JP 2023528561A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- enhancement
- induction
- increase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021013770 | 2020-03-29 | ||
| IN202021013770 | 2020-03-29 | ||
| IN202021030633 | 2020-07-18 | ||
| IN202021030633 | 2020-07-18 | ||
| IN202021054151 | 2020-12-12 | ||
| IN202021054151 | 2020-12-12 | ||
| PCT/IN2021/050325 WO2021199078A2 (en) | 2020-03-29 | 2021-03-30 | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528561A JP2023528561A (ja) | 2023-07-05 |
| JP2023528561A5 true JP2023528561A5 (https=) | 2024-08-16 |
Family
ID=77927896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560025A Pending JP2023528561A (ja) | 2020-03-29 | 2021-03-30 | 宿主細胞の分子および細胞メカニズムとＳＡＲＳ－ＣｏＶ－２タンパク質との相互作用、およびＣＯＶＩＤ－１９を治療するための製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240226120A1 (https=) |
| EP (1) | EP4126913A4 (https=) |
| JP (1) | JP2023528561A (https=) |
| CN (1) | CN115968375A (https=) |
| AU (1) | AU2021247269A1 (https=) |
| BR (1) | BR112022019649A2 (https=) |
| IL (1) | IL296892A (https=) |
| MX (1) | MX2022012165A (https=) |
| WO (1) | WO2021199078A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3179022A1 (en) * | 2020-07-18 | 2021-10-07 | Akseera Pharma Corp. | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19 |
| CN120789031A (zh) * | 2020-07-24 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 大麻二酚在制备治疗冠状病毒感染的药物中的用途 |
| CN115531315B (zh) * | 2022-12-05 | 2023-04-07 | 上海惠盾因泰生物科技有限公司 | 重组人干扰素λ1鼻喷雾剂及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080043A1 (en) * | 2002-03-18 | 2003-10-02 | Immugen Pharmaceuticals, Inc. | Topical formulations of resorcinols and cannibinoids and methods of use |
| EP1559423A1 (en) * | 2004-02-02 | 2005-08-03 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Medicinal acidic cannabinoids |
| WO2012012498A2 (en) * | 2010-07-20 | 2012-01-26 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
| NL2009671C2 (en) * | 2012-10-19 | 2014-04-23 | Fytagoras B V | New antiviral use for acidic cannabinoids. |
| WO2017011785A1 (en) * | 2015-07-15 | 2017-01-19 | National Concessions Group Inc. | Topical antiviral formulations and methods of using the same |
| WO2020257588A1 (en) * | 2019-06-20 | 2020-12-24 | Shaman Naturals, Llc | Compositions for preventing and treating viral infections |
| CN115916336A (zh) * | 2020-02-19 | 2023-04-04 | 施里玛·麦钱特 | 大麻二酚的组合物和治疗用途 |
| US11338010B2 (en) * | 2020-03-30 | 2022-05-24 | Suzhou Kintor Pharmaceuticals, Inc. | Systems, methods, and kits for diagnostics and treatment of viral respiratory infection |
| US20230181484A1 (en) * | 2020-05-11 | 2023-06-15 | Add Advanced Drug Delivery Technologies Ltd. | Uses and Formulations of Cannabinoids |
| US20230338396A1 (en) * | 2020-05-14 | 2023-10-26 | Augusta University Research Institute, Inc. | Cannabidiol as a therapeutic modality for covid-19 |
| CA3179022A1 (en) * | 2020-07-18 | 2021-10-07 | Akseera Pharma Corp. | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19 |
| CN120789031A (zh) * | 2020-07-24 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 大麻二酚在制备治疗冠状病毒感染的药物中的用途 |
-
2021
- 2021-03-30 EP EP21781346.8A patent/EP4126913A4/en not_active Withdrawn
- 2021-03-30 IL IL296892A patent/IL296892A/en unknown
- 2021-03-30 US US17/915,862 patent/US20240226120A1/en not_active Abandoned
- 2021-03-30 AU AU2021247269A patent/AU2021247269A1/en active Pending
- 2021-03-30 BR BR112022019649A patent/BR112022019649A2/pt not_active IP Right Cessation
- 2021-03-30 MX MX2022012165A patent/MX2022012165A/es unknown
- 2021-03-30 CN CN202180038369.XA patent/CN115968375A/zh active Pending
- 2021-03-30 JP JP2022560025A patent/JP2023528561A/ja active Pending
- 2021-03-30 WO PCT/IN2021/050325 patent/WO2021199078A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dastan et al. | Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial | |
| Ye et al. | The pathogenesis and treatment of theCytokine Storm'in COVID-19 | |
| JP2023528561A5 (https=) | ||
| Goyal et al. | Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review | |
| JP2017514911A5 (https=) | ||
| WO2021023263A1 (zh) | 产生安全量的一氧化氮的药物组合物及其用途 | |
| JP2023537229A5 (https=) | ||
| Wang et al. | Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation | |
| LT5079B (lt) | Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai | |
| US9872895B2 (en) | TLR5 ligands, therapeutic methods, and compositions related thereto | |
| Kumar | Novel coronavirus (COVID-19) outbreak: Hope and search for effective therapeutic agent | |
| CN115397410A (zh) | 用于治疗、预防或限制病毒感染发生的方法和组合物 | |
| Stebbing et al. | Kaposi's sarcoma—an update | |
| CN102772398A (zh) | 二氢杨梅素在制备防治流感药物中的应用 | |
| US20230277650A1 (en) | Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv) | |
| WO2022123323A1 (en) | A pharmaceutical composition of artesunate and mefloquine and method thereof | |
| CN107149609B (zh) | 紫菜多糖在制备治疗手足口病毒感染的药物中的应用 | |
| Sinto et al. | Exploring the Potential Treatment for Mpox | |
| Sowmya | Drugs used against COVID-19 | |
| JPWO2025105377A5 (https=) | ||
| KR100805996B1 (ko) | 항-바이러스 의약 및 항암 의약을 제조하기 위한파라폭스바이러스 오비스 균주의 용도 | |
| Patrisio | Host-microbe-drug triad: Role of chloroquine/hydroxychloroquine in Covid-19 treatment-focus on inflammatory cytokine inhibition | |
| WO2024077509A1 (zh) | 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途 | |
| Kovesdi et al. | Natural and artificial viral interference in viral diseases | |
| Yehia et al. | Efficacy of OCTA-H and Octa-Gel Against Herpes Simplex Virus Type 1 Infection |